Swiss National Bank
NVCR icon

Swiss National Bank’s NovoCure NVCR Stock Holding History

Swiss National Bank’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.28M Hold
209,500
– – ﹤0.01% 1781
2025
Q4 		$2.71M Buy
209,500
+4,200
+2% +$53.9K ﹤0.01% 1720
2025
Q3 		$2.65M Buy
205,300
+6,200
+3% +$82.8K ﹤0.01% 1708
2025
Q2 		$3.54M Hold
199,100
– – ﹤0.01% 1468
2025
Q1 		$3.55M Sell
199,100
-3,100
-2% -$70.4K ﹤0.01% 1445
2024
Q4 		$6.03M Buy
202,200
+2,600
+1% +$55K ﹤0.01% 1209
2024
Q3 		$3.12M Hold
199,600
– – ﹤0.01% 1601
2024
Q2 		$3.42M Hold
199,600
– – ﹤0.01% 1514
2024
Q1 		$3.12M Hold
199,600
– – ﹤0.01% 1592
2023
Q4 		$2.98M Sell
199,600
-22,000
-10% -$294K ﹤0.01% 1619
2023
Q3 		$3.58M Sell
221,600
-119,700
-35% -$3.45M ﹤0.01% 1484
2023
Q2 		$14.2M Sell
341,300
-32,600
-9% -$2.02M 0.01% 747
2023
Q1 		$22.5M Sell
373,900
-9,200
-2% -$735K 0.02% 614
2022
Q4 		$28.1M Sell
383,100
-23,948
-6% -$1.8M 0.02% 571
2022
Q3 		$30.9M Sell
407,048
-300
-0.1% -$23.4K 0.02% 554
2022
Q2 		$28.3M Buy
407,348
+2,600
+0.6% +$196K 0.02% 576
2022
Q1 		$33.5M Buy
404,748
+50,300
+14% +$3.71M 0.02% 584
2021
Q4 		$26.6M Sell
354,448
-13,600
-4% -$1.37M 0.02% 622
2021
Q3 		$42.8M Sell
368,048
-7,800
-2% -$1.18M 0.03% 528
2021
Q2 		$83.4M Buy
375,848
+43,048
+13% +$8.37M 0.05% 360
2021
Q1 		$44M Buy
332,800
+8,300
+3% +$1.31M 0.03% 523
2020
Q4 		$56.2M Buy
324,500
+131,000
+68% +$17.9M 0.04% 439
2020
Q3 		$21.5M Buy
193,500
+4,400
+2% +$352K 0.02% 603
2020
Q2 		$11.2M Buy
189,100
+35,500
+23% +$2.33M 0.01% 728
2020
Q1 		$10.3M Buy
153,600
+3,200
+2% +$253K 0.01% 663
2019
Q4 		$12.7M Buy
150,400
+6,200
+4% +$500K 0.01% 687
2019
Q3 		$10.8M Buy
144,200
+2,800
+2% +$224K 0.01% 732
2019
Q2 		$8.94M Buy
141,400
+22,700
+19% +$1.15M 0.01% 801
2019
Q1 		$5.72M Buy
118,700
+4,200
+4% +$202K 0.01% 1003
2018
Q4 		$3.83M Buy
114,500
+5,000
+5% +$183K ﹤0.01% 1140
2018
Q3 		$5.74M Hold
109,500
– – 0.01% 1023
2018
Q2 		$3.43M Buy
109,500
+32,100
+41% +$893K ﹤0.01% 1356
2018
Q1 		$1.69M Buy
77,400
+3,700
+5% +$79.6K ﹤0.01% 1753
2017
Q4 		$1.49M Hold
73,700
– – ﹤0.01% 1838
2017
Q3 		$1.46M Buy
73,700
+3,200
+5% +$62.9K ﹤0.01% 1827
2017
Q2 		$1.22M Hold
70,500
– – ﹤0.01% 1916
2017
Q1 		$571K Hold
70,500
– – ﹤0.01% 2330
2016
Q4 		$553K Hold
70,500
– – ﹤0.01% 2346
2016
Q3 		$602K Hold
70,500
– – ﹤0.01% 2255
2016
Q2 		$823K Buy
+70,500
New +$883K ﹤0.01% 2076

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Swiss National Bank's NVCR Position: Q1 2026 in Review

Swiss National Bank held its NovoCure (NVCR) position steady in Q1 2026 at 209,500 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

Swiss National Bank first reported a position in NVCR in Q2 2016 and has held it in 40 quarters since. The position peaked at $83.4M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Swiss National Bank held 209,500 shares of NovoCure worth $2.28M as of Q1 2026.
  • Swiss National Bank left its NovoCure share count unchanged in Q1 2026.
  • NovoCure made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1781 holding.
  • Swiss National Bank first reported a position in NovoCure in Q2 2016 and has held it in 40 quarters since.
  • Swiss National Bank's NovoCure position peaked at $83.4M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.